Repeated high-dose chemotherapy (HDC) with stem cell support is advocated for curative treatment of epithelial ovarian cancer patients, requiring large quantities of progenitor cell harvest. Although the switchover to peripheral blood stem cell transplantation has generally made possible the harvest of large quantities of progenitor cells, the minimum threshold is still pertinent for planning the safe conduct of HDC. However, as the minimum threshold for safe peripheral blood stem cell transplantation (PBSCT) is not yet established, this study was designed to clarify the minimum amount of progenitor cells required for prompt recovery of hematopoietic. Retrospective analysis was performed on 52 HDCs administered in 37 ovarian cancer patients. After autologous bone marrow aspiration (10 patients) or peripheral blood stem cell harvest (27 patients), colony-forming unit granulocyte macrophage (CFU-GM) were enumerated prior to cryopreservation. Numbers of CFU-GM were again calculated before reinfusion and the patients were divided into eight groups: 0.13-o0.4, 0.4-o0.7, 0.7-o1.0, 1.0-o3.5, 3.5-o5.0, 5.0-o10.0, 10.0-o20.0 and 420.0 ( Â 10 5 /kg) . The minimum CFU-GM threshold ( Â 10 5 /kg) was found to be 1.0-o3.5 for platelets and 3.5-o5.0 for white blood cells. Higher infusion doses did not lead to significant benefits in hematopoietic reconstruction. These results indicate that preservation of a minimum of 7-10 Â 10 5 /kg CFU-GM is recommended for the safe conduct of tandem HDCs.
of CFU-GM; hematopoietic reconstruction; CD34 þ cell In September 1984, we initiated a trial of high-dose chemotherapy (HDC) with autologous bone marrow transplantation (ABMT) in patients with epithelial ovarian cancer, which was switched to peripheral blood stem cell transplantation (PBSCT) in March 1993. Up to March 1997, 105 patients were given 175 courses of HDC followed by hematopoietic stem cell transplantation following reduction surgery to remove as much tumor as possible. As a result, we have obtained good long-term results, and statistically earlier hematopoietic recovery has been identified in the group given PBSCT. [1] [2] [3] [4] [5] Recently, several papers have reported the necessity of applying repeated HDCs for curative treatment of solid tumor malignancies. [6] [7] [8] [9] [10] Mobilization of large quantities of progenitor cells is required for application of several HDCs. Numerous papers have reported on the relationship between the amount of transplanted progenitor cells and hematopoietic recovery. The main factor predicting time to engraftment of autologous blood stem cells is the amount of progenitor cells infused. Several papers report a requirement of more than 2 Â 10 6 /kg of body weight, 11 5 Â 10 6 /kg of body weight 12, 13 and 15 Â 10 6 /kg of body weight 14 CD34 cells for shortening time to hematopoietic engraftment and performing HDC with safety. It is necessary to determine not only minimal progenitor cell requirements for recovery of bone marrow function, but also minimum amounts for prompt recovery enabling safe conduct of HDCs. However, most papers do not discuss a maximum PBSCT dose beyond which no significant increase in benefits is obtained. For analyzing this perspective, retrospective analysis was performed to clarify the relationship between the amount of transplanted progenitor cells and recovery of bone marrow function. Apart from the amount of progenitor cells infused, prior chemotherapy regimens, prior radiation therapy and advanced age have been identified as factors having adverse impact on hematopoietic recovery. [15] [16] [17] This study is an analysis of 52 HDCs performed in 37 patients (median age 49.5 years old) with epithelial ovarian cancer, receiving no previous treatment and given the same treatment and HDC described herein.
Patients and methods

Patient selection and HDC regimen
In all, 37 patients (52 HDCs) were selected from 105 patients (175 HDCs) with epithelial ovarian cancer who had received HDCs between January 1994 and December 1997, at the Gynecologic Department of Tokai University. Among the 105 cases, 58 cases were treated with an HDC regimen of cisplatin þ adriamycin þ cyclophosphamide, and 47 cases with carboplatin þ cyclophosphamide. Of these latter 47 cases, the study was conducted on the 37 cases receiving fairly comparable doses -a total of 52 courses of HDC consisting of either 1200 mg/m 2 (eight courses) or 1500 (44 courses) mg/m 2 of body surface carboplatin (CBDCA) þ 3000 mg/m 2 cyclophosphamide (CPA).
Transplanted progenitor cell counts were 0. ABMT or PBSCT was performed on day 6, and i.v. administration of 300 mg/m 2 filgrastim (granulocyte colony-stimulating factor, G-CSF) was continued from day 7 until white blood cell (WBC) counts exceeded 10 000/ml. No statistical difference was noted in hematopoietic recovery between the two regimens with ABMT (Table 2) .
Bone marrow aspiration and peripheral blood stem cell harvest
Autologous bone marrow harvest (ABMH) was performed as follows. Between 800 and 1000 ml whole blood was aspirated from the bilateral posterior iliac crest under lumbar anesthesia and subsequently cryopreserved at À1901C according to the method described by Gilmore et al. 18 Absence of tumor cells in aspirated bone marrow was confirmed histologically.
Induction chemotherapy for peripheral blood stem cell harvest (PBSCH) consisted of a 1-day administration of cisplatin (50-75 mg/m ), a regimen also having therapeutic properties for ovarian cancers. One or two courses of this regimen were administered as priming for collection of PBSCs. Daily subcutaneous injection of 50-75 mg/body weight of G-CSF was started from the day on which nadir of leukocytes was observed. After induction chemotherapy, a series of two or three daily leukaphereses were performed using COBE Spectra timed on recovery phase from myelosuppression up to a leukocyte count of 7500/ml.
Enumeration of granulocyte macrophage
The number of progenitor cells collected and transplanted are described in Table 3 . Enumeration of CFU-GM was performed by colony assay using commercial colony culture kits 19 (Methocult, GF H 4534 Stem Cell Technologies, Inc.) containing stem cell factor, interleukin 3 and GM-CSF. In our institution, CD34 þ antigen cells were enumerated when the progenitor cells were collected but not when they were transplanted, as assays post-cryopreservation hold the possibility of including denatured or otherwise nonviable cells in the count. The enumeration of stem cells by CFU-GM assay both at the time of collection and upon reinfusion following HDC was considered an acceptable alternative, given results from a preliminary study of 15 cases that revealed a strong correlation of 0.84 between CD34 and CFU-GM (Figure 1 ), indicating 1.0 Â 10 5 /kg CFU-GM as being comparable to 0.73 Â 10 6 / kg CD34 cells. Regarding post-cryopreservation cell loss, comparison of CFU-GM numbers before and after Table 1 Characteristics of 37 patients receiving HDC with hematopoietic progenitor cell support (Table 4) . From these results, analysis in this study has been carried out using CFU-GM values upon reinfusion.
Supportive care
All patients received hyperalimentation via a central venous catheter and were managed in isolated private rooms or laminar airflow bacterial clean rooms. Irradiated (15 Gy) platelets (PLT) were transfused to keep the PLT count 420 000/ml. Intravenous administration of G-CSF (300 mg/ m 2 ) was continued until documentation of bone marrow recovery to 1.0 Â 10 4 /ml WBC.
Statistical analysis
Regarding statistical analysis, a statistician was consulted, and SPSS software was used. Days required for reconstitution of WBC and PLT were regarded as indices of bone marrow function recovery, which are expressed in the bar graphs of Figure 2 . Analysis between groups was performed by the Kruskal-Wallis test working with pairs of all groups, and probability was determined to be significant at levels under 0.05. Subsequently, difference between groups was tested by the Mann-Whitney U-test. Data from first and second transplants were treated equally, as analysis of hemopoietic recovery following first and second transplants in the 15 patients receiving second transplants along five parameters (no. of days WBC o1000/ml, day WBC 41000/ml, no. of days WBC o3000/ml, day PLT 43 Â 10 4 /ml, no. of PLT transfusions) revealed no significant difference.
Results
There is a distinct difference in the number of autologous progenitor cells collected by ABMH and PBSCH. Compared to ABMH, 17 times as many CFU-GM were collected by PBSCH, making it possible to transplant 21 times as many CFU-GM by PBSCT (Table 3) inducing statistically earlier hematopoietic recovery in the PBSCT group (Table 5) . Table 5 shows hematopoietic recovery according to the amount of CFU-GM transplanted by ABMT or PBSCT. Although hematopoietic recovery was obtained in the group receiving under 0.4 Â 10 5 /kg CFU-GM, hematopoietic reconstruction was delayed. There was no clear difference between the amount of transplanted CFU-GM and number of days of WBC counts below 100/ml. However, a negative correlation was noted between the amount of CFU-GM transplanted and: (1) the number of days over which WBC counts were o1000/ml or o3000/ml; (2) days required for restoration of WBC counts to 1000/ml or 3000/ml after ABMT or PBSCT; and (3) restoration of PLT counts to 30 000/ml or 50 000/ml (Table 5 ). (Figure 2a-c) .
As for the recovery in PLT counts, statistically earlier recovery was obtained in groups transplanted in excess of 1.0-o3.5 Â 
Discussion
The usefulness of HDC with stem cell support against epithelial ovarian cancer has been validated through several retrospective analyses demonstrating high response rates and good long-term results. 4, 5, [20] [21] [22] However, these results were obtained in selected patient populations characterized by platinum sensitivity, small volume residual tumor and good performance status at transplant. As such, prospective randomized study was required for drawing definitive conclusions on the usefulness of HDC in ovarian caner. 23 In 2001, the European Group 24 proved, for the first time, the effectiveness of HDC with stem cell support in ovarian cancer by a phase III prospective randomized trial between an HDC with PBSCT group and a conventional dose chemotherapy group in patients with low tumor burden and responsiveness to platinum-based first-line chemotherapy. In addition, several papers [6] [7] [8] [9] [10] reported that sequential HDC with stem cell support produces high clinical response rates in ovarian cancer. These results uphold the use of multicycle HDC for consolidation after achieving maximal response to conventional chemotherapy, which consequently requires large quantities of progenitor cells. This then necessitates clarification of the minimum threshold dose of progenitor cells for prompt recovery of bone marrow function.
In our analysis of 37 patients receiving 52 courses of HDCs with ABMT or PBSCT, the PBSCT group received reinfusion of 21 times as much CFU-GM, resulting in statistically earlier recovery of bone marrow function (Table 5) .
Other papers also report the transplantation of six times 25 and seven times 26 as much CFU-GM in PBSCT groups, resulting in more rapid hematopoietic reconstruction. Several Figure 2 ). Groups receiving less than 1.0 Â 10 5 /kg CFU-GM showed statistically delayed hematopoietic reconstruction in comparison to other groups receiving X3.5 Â 10 5 /kg CFU-GM (Figure 2) . However, no difference was seen in WBC recovery among the four groups Table 5 Hematopoietic recovery after HDC with ABMT or PBSCT support (Figure 2a-c) . As for PLT recovery, the groups transplanted with less than 0.7-o1.0 Â 10 5 /kg CFU-GM showed statistically delayed PLT engraftment (Figure 2d-f) compared to other groups receiving reinfusions of more than 1.0-o3.5 Â 10 5 /kg CFU-GM, while no significant difference was observed among the five groups given more than 1.0-o3.5 Â 10 5 /kg CFU-GM. Perez-Simon et al 32 report the ideal threshold for infusion to be around 2.2 Â 10 6 /kg CD34 þ cells, and that infusion over this dose does not lead to a significant increase in benefits after PBSCT. The CD34 þ population includes not only CFU-GM but other in vitro colony-forming cells. 33, 34 Conversion of Perez-Simon's 2.2 Â 10 6 /kg CD34 þ cells into numbers of CFU-GM according to our calculation based on findings from 15 patients (54 instances), in whom enumeration of both CD34 þ cells and CFU-GM revealed high correlation between the two, yields a value of 3.01 Â 10 5 CFU-GM. Being quite similar to our results, we believe that this agreement may be taken as indication of the validity of our evaluation.
From our findings, the following conclusions were drawn. Transplantation of 3.5-o5.0 Â 10 5 /kg CFU-GM for neutrophilic reconstruction, and of 1.0-3.5 Â 10 5 /kg CFU-GM for PLT reconstruction appears to be both adequate and optimal, as transplantation of CFU-GM over these doses induces no additional benefits in terms of hematopoietic reconstruction. Therefore, harvest of 7-10 Â 10 5 /kg CFU-GM, or converting to CD34 þ cells, 5.1-7.3 Â 10 6 /kg CD34 þ cells, is recommended for the safe performance of tandem HDCs, capable of circumventing delayed hematopoietic reconstruction incurring long hospitalizations, improving the patients' quality of life, and with the additional benefit of contributing to significant reductions in costs.
